Compare Amylx Pharmaceuticals Inc (AMLX) vs Packaging Corporation of America (PKG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Packaging Corporation of America — how do they compare? Amylx Pharmaceuticals Inc trades at $17.65 (market cap $1.98B), while Packaging Corporation of America trades at $228.5 (market cap $20.38B). The key difference: Packaging Corporation of America is far larger — about 10.3× Amylx Pharmaceuticals Inc's market cap, and Packaging Corporation of America pays a 2.62% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | PKG | |
|---|---|---|
Market Cap | $1.98B | $20.38B |
Sector | Health | Technology |
52-Week High | $18.70 | $246.31 |
52-Week Low | $7.64 | $191.41 |
Enterprise Value | $1.70B | $24.21B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Packaging Corporation of America (PKG) trades at $228.77, up 1.91% with a bullish technical signal. The company reported mixed Q1 2026 earnings with $2.40 EPS beating estimates, though revenue growth faces margin pressure. Analyst consensus is mixed with 34.6% buy ratings and a $253 price target. Recent 20% dividend increase signals management confidence amid elevated input costs.
PKG offers steady dividend income with potential upside to analyst targets, but faces headwinds from cost inflation and competitive pressures. The stock's 27.8 P/E suggests full valuation, requiring sustained earnings growth to justify current levels. Near-term performance hinges on Q2 results and operational efficiency improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
